A single blood draw. No procedure risk to mother or fetus.
01
CLIP: BLOOD DRAWWatermarked placeholder, pending license
Non-invasive fetal sequencing
Revolutionizing prenatal care with scalable genomics.
The first fetal sequencing test to deliver comprehensive genetic screening at NIPT scale, with no invasive procedure.
22,995
Genes screened per test
8 years
of R&D and validation
Zero
Procedure risk to the fetus
01FGI's Approach
Every prenatal test today is a trade-off
Non-invasive testing misses most clinically relevant conditions. Invasive testing catches them, but carries real risk.
02NIFS
How a sample becomes a result.
The sample is processed and prepared for sequencing within hours of collection.
02
CLIP: CENTRIFUGE / PROCESSINGWatermarked placeholder, pending license
Millions of data points resolve into a clear genomic result.
03
CLIP: DNA SEQUENCING VISUALIZATIONWatermarked placeholder, pending license
03Our Mission
We're building the infrastructure for a new standard of prenatal care, scientifically rigorous, responsibly deployed.
Where FGI is today
Validating NIFS through prospective studies, ahead of a planned launch.
What FGI is building toward
Population-scale screening that replaces NIPT as the standard of care.
Founders
Founded by leaders in genomic and maternal-fetal medicine.
Three physician-scientists from Harvard, Columbia, and the Broad Institute.
Publication · NEJM
Peer-reviewed work behind the platform, beginning with the NEJM paper.
Clinical · Validation
Validating NIFS through prospective studies, ahead of a planned launch.
Partners · Laboratories
Establishing partnerships with commercial laboratories to expand delivery of NIFS.